NASDAQ · VKTX
Healthcare · Biotechnology
$29.95
Down-$1.58 (-5.01%)
Updated Sep 16, 2026, 9:24 AM
SID Score
4.6/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
VKTX closed at $29.95 after 20 trading sessions, down 10.25% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $31.21 | $31.25 | $29.70 | $29.95 | 2.81M |
| Sep 14, 2026 | $31.70 | $32.43 | $31.39 | $31.53 | 1.85M |
| Sep 11, 2026 | $32.26 | $33.05 | $31.70 | $31.98 | 2.21M |
| Sep 10, 2026 | $32.50 | $32.65 | $31.87 | $32.13 | 1.72M |
| Sep 9, 2026 | $33.36 | $34.60 | $32.59 | $32.70 | 2.04M |
| Sep 8, 2026 | $34.63 | $34.81 | $33.53 | $33.68 | 1.87M |
| Sep 4, 2026 | $33.75 | $34.95 | $33.56 | $34.87 | 1.4M |
| Sep 3, 2026 | $34.00 | $34.45 | $33.68 | $33.98 | 1.39M |
| Sep 2, 2026 | $33.67 | $34.75 | $32.7708 | $33.50 | 1.57M |
| Sep 1, 2026 | $32.61 | $33.71 | $32.38 | $33.67 | 1.68M |
| Aug 31, 2026 | $31.77 | $32.98 | $31.70 | $32.78 | 1.78M |
| Aug 28, 2026 | $33.75 | $33.86 | $31.98 | $32.16 | 2.38M |
| Aug 27, 2026 | $34.33 | $34.39 | $33.15 | $33.86 | 2.21M |
| Aug 26, 2026 | $34.09 | $34.75 | $33.802 | $34.38 | 1.14M |
| Aug 25, 2026 | $33.67 | $34.994 | $33.43 | $34.17 | 2.1M |
| Aug 24, 2026 | $33.75 | $33.765 | $32.61 | $33.23 | 1.75M |
| Aug 21, 2026 | $34.79 | $34.98 | $33.47 | $33.89 | 1.5M |
| Aug 20, 2026 | $35.79 | $35.79 | $33.9618 | $34.36 | 1.67M |
| Aug 19, 2026 | $34.10 | $36.26 | $33.8301 | $35.98 | 2.69M |
| Aug 18, 2026 | $33.42 | $33.94 | $33.00 | $33.37 | 1.19M |
The latest Smart Investors Daily articles mentioning VKTX.
VKTX research
Company profile and research snapshot.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 11, 2026 | JP Morgan | Overweight | — |
| Jul 30, 2026 | Canaccord Genuity | Buy | — |
| May 28, 2026 | Lake Street | Buy | — |
| Apr 30, 2026 | Cantor Fitzgerald | Overweight | — |
| Mar 23, 2026 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Yahoo · Sep 11, 2026
The average brokerage recommendation (ABR) for Viking Therapeutics (VKTX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Yahoo · Sep 10, 2026
Viking Therapeutics, Inc. (VKTX) closed the most recent trading day at $32.13, moving 1.74% from the previous trading session.
Yahoo · Sep 10, 2026
Axsome is already selling drugs with 65% revenue growth, while Viking bets on obesity treatments still in trials, a classic choice between proven sales and blockbuster potential.
Yahoo · Sep 9, 2026
Viking Therapeutics, Inc. (VKTX) closed at $32.7 in the latest trading session, marking a -2.91% move from the prior day.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning VKTX.
